Advances in IKBKE as a potential target for cancer therapy
- PMID: 31733040
- PMCID: PMC6943080
- DOI: 10.1002/cam4.2678
Advances in IKBKE as a potential target for cancer therapy
Abstract
IKBKE (inhibitor of nuclear factor kappa-B kinase subunit epsilon), a member of the nonclassical IKK family, plays an important role in the regulation of inflammatory reactions, activation and proliferation of immune cells, and metabolic diseases. Recent studies have demonstrated that IKBKE plays a crucial regulatory role in malignant tumor development. In recent years, IKBKE, an important oncoprotein in several kinds of tumors, has been widely found to regulate a variety of cytokines and signaling pathways. IKBKE promotes the growth, proliferation, invasion, and drug resistance of various cancers. This paper makes a detailed review that focuses on the recent discoveries of IKBKE in the malignant tumors, and puts forward that IKBKE is becoming an important therapeutic target for clinical treatment, which has been more and more realized.
Keywords: IKBKE; NF-κB; signaling pathway; small molecule inhibitors.
© 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Conflict of interest statement
The authors disclose no conflict of interest.
Figures
References
-
- Shimada T, Kawai T, Takeda K, et al. IKK‐i, a novel lipopolysaccharide inducible kinase that is related to IkappaB kinases. Int Immunol. 1999;11(8):1357‐1362. - PubMed
-
- Peters RT, Liao SM, Maniatis T. IKKepsilon is part of a novel PMA‐inducible IkappaB kinase complex. Mol Cell. 2000;5(3):513‐522. - PubMed
-
- Chien Y, Kim S, Bumeister R, et al. RalB GTPase‐mediated activation of the IkappaB family kinase TBK1 couples innate immune signaling to tumor cell survival. Cell. 2006;127(1):157‐170. - PubMed
-
- Kawai T, Akira S. Signaling to NF‐kappaB by Toll‐like receptors. Trends MolMed. 2007;13(11):460‐469. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
